In $185M deal, Merz purchases Parkinson’s, MS therapeutics from Acorda
Click Here to Manage Email Alerts
Merz Therapeutics announced that it has acquired assets from Acorda Therapeutics Inc. in development to treat Parkinson’s disease and multiple sclerosis.
According to a press release from Merz, the $185 million transaction brings two novel therapeutics that target neurodegenerative conditions into its pipeline: Inbrija, (levodopa inhalation powder) administered through the proprietary tech platform for those with PD; and Fampyra (fampridine), a prolonged release tablet intended to assist patients with MS who have walking difficulties.
Inbrija is intended as adjunct to address “off” symptoms of PD for individuals already prescribed carbidopa/levodopa.
Fampyra is related to Ampyra (dalfampridine), which was previously approved by the FDA for use in the United States and sold in the European Union and other territories as Fampyra.
“This deal demonstrates Merz Therapeutics’ interest and ability to acquire assets that will deliver greater, sustainable outcomes for more people living with neurological disorders,” Merz Therapeutics CEO Stefan König said in the release. “Merz Therapeutics is well poised to build on what we have accomplished in the specialty neurology space, strengthening our market position in Parkinson’s disease and expanding into the MS segment.”